Intelligent Bio Solutions Expands Global Reach with Latin American Spanish Language Integration into Drug Screening System
Company expands Intelligent Fingerprinting Drug Screening System multilingual capabilities to meet growing demand across Latin American Spanish-speaking markets
Latin American drug screening market projected to reach USD 1.1 billion by 2030
Expansion is part of major multilingual Drug Screening System upgrade, targeting over 4 billion potential users worldwide
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the integration of Latin American Spanish into its Intelligent Fingerprinting Drug Screening System (the “System”). The enhancement allows users to operate the System in English, Arabic, and Latin American Spanish, extending the platform’s usability across diverse, international settings.
Spanish is the fourth most spoken language in the world and the second most spoken language in the U.S. It is the official language in over 20 countries, including the majority of countries in Latin America, and is spoken by over 500 million people globally1. By incorporating Latin American Spanish into the System, INBS strengthens its support for Spanish-speaking markets and regional distribution partners. This update increases accessibility for end-users across North America, Central America, South America, and Europe, aligning with the Company’s strategic growth plans.
“As we see increased interest from Spanish-speaking distributors and companies, we must ensure our solution remains accessible and relevant to these markets. Integrating Latin American Spanish into our System is a key step toward opening new opportunities for future growth,” said Harry Simeonidis, President & CEO at Intelligent Bio Solutions. “As demand grows, so does the value of business localization. Our product stands out in the market by offering local language capabilities, something most solutions don’t provide. It’s a clear differentiator.”
The Latin American drug screening market is projected to reach USD 1.1 billion by 2030, driven by increasing public safety initiatives and growing demand for workplace compliance programs2. In Europe, Spain’s drug testing market is expected to reach USD 368.4 million by 20303, reflecting similar trends in regulation and adoption. INBS’ multilingual capabilities position the Company to better serve evolving testing needs through an intuitive, localized platform experience.
This development forms part of the Company’s major multilingual system upgrade announced earlier this year. The complete multilingual upgrade will support multiple languages spoken across the Americas, Europe, Asia Pacific and the Middle East, making the System accessible to over 4 billion speakers worldwide4. The added capability supports a broader growth strategy to expand on a foundation of over 400 accounts across 19 countries and to penetrate new markets and regions. The Latin American Spanish enhancement is a key development milestone as the Company prepares to enter the multi-billion-dollar U.S. market this year, following its FDA 510(k) submission in December 2024.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit:
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
|
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
_____________________________
Hyperlinks and website references in this release are provided for convenience only, and do not incorporate the referenced content into this release.
1 Statista 2025. Countries with the largest number of native Spanish speakers worldwide in 2024. Available at:
2 Grand View Research 2025. Latin America Drug Screening Market Size & Outlook. Available at:
3 Grand View Research 2025. Spain Drug Screening Market Size & Outlook, 2018-2030. Available at:
4 Ethnologue, 2024. The Ethnologue 200. Available at:
